Clinical trials: Multi-food Allergy
Food Allergy
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
The purpose of this study is testing the use of Enhanced-Butanol purified-Food Allergy Herbal Formula-2 (E-B-FAHF-2) Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help…
- Trial name
- FAHF-2 (NCT06103656)
- Testing
- Drug: Chinese Herbal Medication, Drug: Omalizumab
- Volunteers
- 33 people
- Sponsor
- New York Medical College
Food Allergy in Children
Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy
The aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose against food allergy in young children (0.5-3 years) is safe and effective, a method to cure food allergy…
- Trial name
- INFO-DK (NCT07899359)
- Testing
- OIT multiallergen powder
- Volunteers
- 80 people
- Sponsor
- Odense University Hospital
Allergy
Acceptability and Palatability Study of Paediatric Amino Acid Feed
Product acceptability and palatability data from a minimum of 15 participants are required to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) for Ireland for…
- Trial name
- NCT06547346
- Testing
- Alfamino Junior
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Société des Produits Nestlé (SPN)
Food Allergy
Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food…
- Trial name
- MAP-X (NCT02643862)
- Testing
- Xolair
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Food Allergy
Multi OIT to Test Immune Markers After Minimum Maintenance Dose
Few studies have been conducted to optimize safety of multiple food allergen oral immunotherapy (OIT) in conjunction with Omalizumab as well as to identify the immunological mechanism(s) underlying any long-lasting effects of…
- Trial name
- NCT03181009
- Testing
- Omalizumab, Food Flour Allergens
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andrew Long, PharmD
Allergy, Nut
Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy
The LMNOP trial will be a 2-armed, open-label, randomised controlled trial (RCT), 2:1. Over a period of 18 months, children in the Multi-Nut Oral Immunotherapy Treatment (OIT) Group (experimental arm) will undergo low dose OIT to…
- Trial name
- LMNOP (NCT05049512)
- Testing
- Multi-nut OIT
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Murdoch Childrens Research Institute
Egg Allergy
Safe Administration of Flu Vaccine to Egg Allergic Children
Historically, providing influenza vaccination of egg allergic children and young adults (EAC) with a history of anaphylaxis to egg, or other severe symptoms of an allergic reaction to egg (e.g., severe hives, swelling, or…
- Trial name
- SAFE (NCT01264601)
- Testing
- Trivalent Influenza Vaccine
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Michigan
Food Allergy
Low Dose Multi-OIT for Food Allergy (LoMo)
Oral immunotherapy (OIT) is a food allergy treatment where small amounts of the food a child is allergic to is eaten and gradually increased over time with the aim to be able to eat a certain amount of the allergen without…
- Trial name
- LoMO (NCT03799328)
- Testing
- multi-OIT
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- The Hospital for Sick Children
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Food IgE-mediated Allergy, Immunotherapy
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance…
- Conditions
- Food IgE-mediated Allergy, Immunotherapy, Omalizumab, Physiological Effects of Drugs
- Trial name
- BOOM (NCT04045301)
- Testing
- Omalizumab 16mg/kg, Omalizumab 8mg/kg, Multi-food oral immunotherapy (OIT)
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Philippe Bégin
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
To assess the frequency and nature of adverse events in infants fed a free amino acid based infant formula.
- Conditions
- Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome
- Trial name
- EAGLE (NCT02953223)
- Testing
- Free amino acid infant formula
- Where
- 29 sites in United States
- Volunteers
- 144 people
- Sponsor
- Société des Produits Nestlé (SPN)
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Allergy
Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals
The purpose of the study is to test a food supplement to: Show that the food supplement is well tolerated and safe to feed to infants; Find out how often parents/caregivers feed their infants the food supplement; Find out how…
- Trial name
- NCT03667118
- Testing
- Food Supplement
- Where
- United States
- Volunteers
- 705 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hypersensitivity, Food Allergy
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Food allergy is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15…
- Conditions
- Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity
- Trial name
- NCT03679676
- Testing
- Omalizumab, Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Stanford University
Food Allergy
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
- Trial name
- NCT06437171
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AAADRS Clinical Research Center
Food Allergy
E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to…
- Trial name
- NCT02879006
- Testing
- Chinese Herbal Medication, Omalizumab, Multi OIT
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Xiu-Min Li
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Food Allergy
Open-label Extension Study of ADP101
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
- Trial name
- NCT05243719
- Testing
- ADP101
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Peanut Allergies
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake.
- Trial name
- NCT07287033
- Testing
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabylon AG
Type 1 Diabetes, Allergic Rhinitis
Intervention in Chronic Pediatric Patients and Their Families.
This project consists of a psychological intervention in patients and their families with different chronic diseases in order to carry out a comparative study between medical pathologies to know which are the protective or risk…
- Conditions
- Type 1 Diabetes, Allergic Rhinitis, Allergic Asthma, Asthma
- Trial name
- FACTORADAPT (NCT04476433)
- Testing
- Ten Vida (10Vida)
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Valencia